BiogenBIIBEarnings & Financial Report
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
BIIB Q4 2025 Key Financial Metrics
売上高
$2.3B
粗利益
$1.8B
営業利益
N/A
純利益
$-48.9M
粗利益率
78.3%
営業利益率
N/A
純利益率
-2.1%
前年比成長
-7.1%
EPS
$-0.35
資金フロー
Biogen Q4 2025 Financial Summary
Biogen reported revenue of $2.3B for Q4 2025, with a net profit of $-48.9M (-2.1% margin). Cost of goods sold was $495.5M, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.3B |
|---|---|
| Net Profit | $-48.9M |
| Gross Margin | 78.3% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Biogen Annual Revenue by Year
Biogen annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.9B).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.9B |
| 2024 | $9.7B |
| 2023 | $9.8B |
| 2022 | $10.2B |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $2.29B | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B |
| 前年比成長 | -7.0% | 0.4% | -2.5% | 2.9% | 6.1% | 7.3% | 2.8% | -7.1% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $26.57B | $26.80B | $28.31B | $28.05B | $28.03B | $28.33B | $29.21B | $29.44B |
| 総負債 | $11.35B | $10.91B | $11.95B | $11.33B | $11.05B | $10.70B | $11.00B | $11.18B |
| 株主資本 | $15.21B | $15.89B | $16.36B | $16.72B | $16.98B | $17.63B | $18.21B | $18.26B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $553.2M | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.27B | $511.9M |
Other Health Care Companies
ABBV
AbbVie
売上高
$15.8B
純利益
$186.0M
AMGN
Amgen
売上高
$9.9B
純利益
$1.3B
GILD
Gilead Sciences
売上高
$7.8B
純利益
$3.1B
INCY
Incyte
売上高
$1.5B
純利益
$299.3M
MRNA
Moderna
売上高
$1.0B
純利益
$-200.0M
REGN
Regeneron Pharmaceuticals
売上高
$3.9B
純利益
$844.6M
VRTX
Vertex Pharmaceuticals
売上高
$3.2B
純利益
$1.2B
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
A
Agilent Technologies
売上高
$1.9B
純利益
$434.0M
ALGN
Align Technology
売上高
$995.7M
純利益
$56.8M